二氢丹参酮 I 通过 DNA 损伤和 EGFR 通路抑制肝癌细胞增殖。
Dihydrotanshinone I inhibits hepatocellular carcinoma cells proliferation through DNA damage and EGFR pathway.
机构信息
Department of Hepatopancreatobiliary Surgery, The First People's Hospital of Yongkang, Yongkang, Zhejiang, China.
Department of Pharmacy, The First People's Hosipital of Yongkang, Yongkang, Zhejiang, China.
出版信息
PeerJ. 2023 Mar 13;11:e15022. doi: 10.7717/peerj.15022. eCollection 2023.
BACKGROUND
The incidence and mortality of hepatocellular carcinoma (HCC) are globally on the rise. Dihydrotanshinone I, a natural product isolated from has attracted extensive attention in recent years for its anti-tumour proliferation efficiency.
METHODS
Cell proliferations in hepatoma cells (Huh-7 and HepG2) were evaluated by MTT and colony formation assays. Immunofluorescence (IF) of 53BP1 and flow cytometry analysis were performed to detect DNA damage and cell apoptosis. Furthermore, network pharmacological analysis was applied to explore the potential therapeutic targets and pathway of dihydrotanshinone I.
RESULTS
The results showed that dihydrotanshinone I effectively inhibited the proliferation of Huh-7 and HepG2 cells. Moreover, dihydrotanshinone I dose-dependently induced DNA-damage and apoptosis . Network pharmacological analysis and molecular simulation results indicated that EGFR might be a potential therapeutic target of dihydrotanshinone I in HCC. Collectively, our findings suggested that dihydrotanshinone I is a novel candidate therapeutic agent for HCC treatment.
背景
肝细胞癌（HCC）的发病率和死亡率在全球呈上升趋势。二氢丹参酮 I 是从 中分离得到的一种天然产物，近年来因其抗肿瘤增殖效率而受到广泛关注。
方法
通过 MTT 和集落形成实验评估肝癌细胞（Huh-7 和 HepG2）的细胞增殖。通过免疫荧光（IF）检测 53BP1 和流式细胞术分析来检测 DNA 损伤和细胞凋亡。此外，还应用网络药理学分析来探讨二氢丹参酮 I 的潜在治疗靶点和通路。
结果
结果表明，二氢丹参酮 I 能有效抑制 Huh-7 和 HepG2 细胞的增殖。此外，二氢丹参酮 I 呈剂量依赖性诱导 DNA 损伤和细胞凋亡。网络药理学分析和分子模拟结果表明，EGFR 可能是二氢丹参酮 I 在 HCC 治疗中的一个潜在治疗靶点。综上所述，我们的研究结果表明，二氢丹参酮 I 是治疗 HCC 的一种新型候选治疗药物。
Zotero 插件